Candida auris and Biofilm: Why Surface Survival — Not Lab Kill Claims — Is the Real Infection-Prevention Problem

Your disinfectant carries a Candida auris kill claim. Your EVS team observes the manufacturer's contact time. Your infection prevention committee approved the SKU because it appears on EPA List P.

So here is the uncomfortable question:

Can that disinfectant actually reach C. auris where it lives on a patient room floor — inside biofilm?

EPA efficacy testing doesn't happen on a patient floor. It happens on a hard, non-porous coupon in a lab — a surface that is scrupulously clean, freshly inoculated, and free of the one variable that defines the real world: biofilm.

That gap between the lab bench and the patient room is where Candida auris outbreaks are born.

C. auris Is No Longer a Regional Story

As of August 2026, CDC surveillance data shows clinical cases of Candida auris reported in 27 states. What began as a handful of coastal clusters is now a national colonization and transmission problem, with the sharpest growth in long-term acute care hospitals (LTACHs), skilled nursing facilities with ventilator units, and the tertiary hospitals that receive their transfers.

The superbug fungus Candida auris is not just spreading. It is spreading despite the fact that most affected facilities are already using EPA List P–registered disinfectants.

Which brings us back to biofilm.

Why Candida auris Is a Problem for Healthcare Facilities

Candida auris is a problem for healthcare facilities because it behaves like almost nothing else in the fungal world:

• It colonizes skin persistently. Patients can shed the organism for months without symptoms.
• It survives on dry surfaces for weeks — and inside biofilm, for months.
• It resists multiple antifungal drug classes, including echinocandins, azoles, and, in some isolates, amphotericin B.
• It is frequently misidentified by standard lab methods, delaying isolation and cohorting.
• It shelters within biofilm on high-touch surfaces.

The last point is the one most disinfection programs are not built for.

The 93% Number That Should Reframe Your Program

Environmental surveillance research indicates that 93% of critical surfaces in hospitals harbor biofilm. Not visible soil. Not "opportunities for improved cleaning." Biofilm — a structured, extracellular polymeric matrix that shields microorganisms from disinfectants, desiccation, and mechanical removal.

If nearly every high-touch surface in your facility is already colonized by a biofilm community, and C. auris preferentially embeds itself within those communities, then the question is no longer "Does my disinfectant kill C. auris?"

The question is: "Can my disinfectant reach C. auris in the first place?"

What the Lab Test Doesn't Tell You

EPA List P registration is a meaningful floor — but it is a floor, not a ceiling. To earn a C. auris claim, a product must demonstrate efficacy under standardized conditions. Those conditions bear little resemblance to a working patient room.

A product can pass every EPA test and still fail on a patient floor — not because the chemistry is wrong, but because the conditions are wrong.

This is the false choice EarthSafe consistently pushes back on: the industry has been trained to equate "kill claim on the label" with "protection in the field." Those are not the same thing.

How Candida auris Uses Biofilm to Survive Cleaning

Educational context drawn from the TIPS Master Class "Candida auris & Biofilm: Proactive Measures for Mitigating Fungal MDROs," presented by Nicole Slacik (EVP Healthcare, EarthSafe) with Dr. Rodney Rohde of Texas State University, along with published work by J. Darrel Hicks (author of Infection Prevention For Dummies) in Healthcare Facilities Today and biofilm explainers from Infection Control Today, converges on three mechanisms every EVS director and infection preventionist should understand.

1. C. auris Establishes Itself in Biofilm on Everyday Surfaces

C. auris readily takes hold in biofilm on the abiotic surfaces that fill a patient room — plastic, stainless steel, silicone, polyurethane. Once established, that matrix reduces antifungal and disinfectant penetration by orders of magnitude compared to free-floating cells.

2. It Hides Inside Bacterial Biofilm

On real patient-room surfaces, C. auris doesn't wait for a pristine substrate. It integrates into existing polymicrobial biofilms already colonizing bed rails, overbed tables, IV pumps, call buttons, and floors. The bacterial matrix provides shelter; C. auris contributes drug resistance. It is a mutually reinforcing arrangement.

3. Surfaces Recontaminate Within Hours

Environmental studies of high-touch hospital surfaces consistently show bioburden returning to pre-clean levels within 4–6 hours of terminal or daily cleaning. In a room housing a colonized patient, that recontamination is not neutral — it is a re-seeding event for the next biofilm generation.

Study data referenced in the field indicates C. auris can persist on dry surfaces for weeks, and within protected biofilm environments for months.

Pointed Questions to Ask About Your Current Program

If you lead EVS, infection prevention, or operations at a facility with C. auris exposure — or transfer relationships with facilities that have it — these are the questions worth putting on the table at your next environment-of-care meeting:

1. Does our disinfectant carry claims against bacteria in biofilm — published efficacy data in claim language, not just planktonic-cell results?
2. What is our disinfectant's dwell time — is it 4 minutes or less?
3. Has our disinfectant been studied to show Continuously Active Disinfection for 24 hours?
4. Are we using disposable wipes vs. microfiber cloths in isolation / special precautions rooms?
5. Are we using an enhanced disinfection method — electrostatic application, no-touch systems — to reach the surfaces our manual process misses?
6. Do we have a building-wide sporicidal, or are we relying on a quat-only program that biofilm and C. auris are known to tolerate?
7. How are we handling shared mobile equipment — the vector most likely to move C. auris between rooms and units?

If any of those questions produces silence, that silence is your action item.

What a Candida auris Cleaning Protocol Should Actually Include

A defensible C. auris protocol has to do more than name a product. It has to address biofilm, coverage, and verification.

Chemistry

• Use an EPA List P–registered disinfectant with demonstrated efficacy against C. auris.
• Prioritize sporicidal disinfectant chemistries — such as hypochlorous-generating or peracid-based systems. The same oxidative mechanisms that address C. difficile spores are generally more disruptive to biofilm matrix than quats alone.
• Consider pH. Chemistry selection should weigh pH alongside efficacy — and verify surface and equipment compatibility, because chemistries that degrade materials over time create the micro-topography biofilm loves.

Biofilm Claim

• Look for EPA-registered claims against bacteria in biofilm. Current biofilm claims on the EarthSafe master label cover Pseudomonas aeruginosa and Staphylococcus aureus (general and drain). 

Continuously Active Disinfection

• Ask whether the disinfectant has been studied for Continuously Active Disinfection (CAD) — residual efficacy over a 24-hour window — which directly addresses the recontamination interval between manual cleanings.

Coverage

• Manual wiping alone will miss surfaces. Electrostatic spray application provides wraparound coverage on the three-dimensional, irregular surfaces — IV poles, wheelchair frames, bed rails — where biofilm accumulates and C. auris hides.
• Address soft surfaces and shared mobile equipment on the same cadence as hard surfaces.

Frequency

• High-touch surfaces in C. auris precautions rooms need cleaning intervals aligned with the 4–6 hour recontamination reality — not once-a-shift habit.

Verification

• Environmental cultures provide the feedback loop a compliance checklist alone cannot.

C. auris Precautions Beyond Cleaning

• Single-room placement or cohorting of colonized/infected patients.
• Contact Precautions with gowns and gloves.
• Dedicated or single-use equipment where feasible.
• Inter-facility communication at transfer — colonization status must travel with the patient.
  

What EarthSafe Recommends EVS and IP Leaders Do This Quarter

1. Audit your current disinfectant against EPA List P. Confirm the C. auris claim, contact time, and surface compatibility in writing.
2. Add an enhanced disinfection layer — electrostatic application — for terminal cleans, transfer cleans, and outbreak response.
3. Introduce biofilm into your training vocabulary. Frontline EVS technicians who understand why dwell time matters clean differently than those who only know that it matters.
4. Establish transfer protocols with referring LTACHs and SNFs. Candida auris transmission is very often an admissions-desk problem before it is an EVS problem.

FAQ: Candida auris on Environmental Surfaces

Is Candida auris airborne? C. auris is not considered a primarily airborne pathogen in the way Mycobacterium tuberculosis or measles are. Transmission is predominantly via contact — colonized skin, contaminated hands, and contaminated surfaces and equipment. However, activities like bed-making or moving objects in the room can redistribute the organism onto nearby surfaces, which is one reason environmental cleaning and coverage-focused application methods matter so much.

What is the Candida auris death rate? CDC has reported crude mortality among patients with invasive C. auris infection — particularly bloodstream infection — in the range of 30–60%. That figure reflects the underlying severity of illness in affected patient populations as much as the organism itself. Colonization alone is not fatal, but it is the reservoir from which invasive infections emerge — which is why environmental control is a mortality-reduction strategy, not just a compliance exercise.

What does Candida auris look like on surfaces? Nothing. C. auris is invisible to the naked eye on environmental surfaces. There is no visible biofilm signature, no discoloration, no odor. This is precisely the problem: EVS teams cannot see where the risk is, which is why protocol, coverage, and verification — rather than visual inspection — have to drive the program.

What should a Candida auris cleaning protocol include? At minimum: an EPA List P–registered disinfectant used at labeled contact time; consideration of the real-world environment with biofilm versus testing conditions in a lab; electrostatic or comparable coverage-focused application for three-dimensional and shared equipment; cleaning frequencies aligned with 4–6 hour recontamination windows on high-touch surfaces; documented training on dwell time and wipe saturation; and verification through environmental culture audits. Precautions extend beyond cleaning to single-room placement, contact precautions, and transfer communication.

The Bottom Line

A Candida auris kill claim on a label is a necessary starting point. It is not a finish line. The organism's real advantage is not its resistance to any single molecule. It is its ability to embed itself inside biofilm structures that most disinfection programs were never designed to penetrate. Lab efficacy is measured in minutes on clean coupons. Patient-room reality is measured in weeks of surface survival, months of biofilm persistence, and 4–6 hour recontamination cycles.

Closing that gap requires a program built around biofilm — not around a SKU.

Talk to EarthSafe

If you are re-evaluating your C. auris program — or your infection prevention committee is asking harder questions about what your current disinfectant actually does on a patient floor — we would welcome the conversation. Request the TIPS Master Class recording "Candida auris & Biofilm: Proactive Measures for Mitigating Fungal MDROs," or schedule a program review with our healthcare team.

References

1. TIPS Master Class: Slacik, N. & Rohde, R. Candida auris & Biofilm: Proactive Measures for Mitigating Fungal MDROs. https://masterseries.events/portfolio/candida-auris-biofilm-proactive-measures-for-mitigating-fungal-mdros/
2. Hicks, J.D. "What You Should Know About C. Auris and Biofilm." Healthcare Facilities Today.
3. "How does biofilm make Candida auris worse? An expert explains." Infection Control Today.
4. Centers for Disease Control and Prevention. Candida auris surveillance / tracking (clinical cases by state, 2026). https://www.cdc.gov/candida-auris/
5. U.S. EPA. List P: Antimicrobial Products Registered with EPA for Claims Against Candida auris. https://www.epa.gov/pesticide-registration/list-p
6. Hu, H., et al. (2015). "Intensive care unit environmental surfaces are contaminated by multidrug-resistant bacteria in biofilms." Journal of Hospital Infection, 91(1), 35–44. https://www.journalofhospitalinfection.com/article/S0195-6701(15)00258-3/abstract — dry-surface biofilm prevalence on ICU surfaces (93% figure).
7. CDC — Candida auris mortality and clinical information. https://www.cdc.gov/candida-auris/hcp/clinical-overview/